Skip to main content
Vigonvita Life Sciences Co., Ltd. logo

Vigonvita Life Sciences Co., Ltd. — Investor Relations & Filings

Ticker · 2630 ISIN · CNE1000076N3 HKEX Manufacturing
Open in API
Filings indexed 44 across all filing types
Latest filing 2026-03-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2630

About Vigonvita Life Sciences Co., Ltd.

http://www.vigonvita.cn

Vigonvita Life Sciences Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule drugs. The company operates an integrated R&D platform targeting high-need therapeutic areas, specifically neurological and neuropsychiatric disorders, reproductive health, and viral infections. Its comprehensive pipeline includes the oral nucleoside antiviral candidate MINDVY® (VV116), which has been clinically studied for COVID-19 and RSV, and ONVITA® (TPN171). Vigonvita emphasizes high-quality development, evidenced by its participation in significant national programs, including the National Key R&D Program and the Major New Drug Innovation Technology Major Project, often involving international clinical research collaborations.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2026
Regulatory Filings Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and public float. As it is a recurring regulatory filing that does not fit into specific categories like 'Share Issue' (which is for specific events) or 'Annual Report', it falls under the 'Regulatory Filings' (RNS) category.
2026-03-04 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (EGM) issued by Vigonvita Life Sciences Co., Ltd. It outlines the date, time, location, and the specific resolution to be voted upon (the H Share Award Scheme). It also provides instructions for shareholders regarding proxy appointments and voting procedures. This document is a solicitation of proxies and information for an upcoming shareholder meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-03-02 English
PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, MARCH 19, 2026
Proxy Solicitation & Information Statement Classification · 100% confidence The document is explicitly titled 'PROXY FORM FOR THE EXTRAORDINARY GENERAL MEETING'. It provides instructions for shareholders to appoint a proxy to vote on their behalf at an upcoming meeting, including specific fields for voting 'For', 'Against', or 'Abstain' on resolutions. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-03-02 English
PROPOSED ADOPTION OF THE H SHARE AWARD SCHEME AND NOTICE OF EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a circular issued by Vigonvita Life Sciences Co., Ltd. to its shareholders. It provides detailed information regarding the 'Proposed Adoption of the H Share Award Scheme' and includes a 'Notice of Extraordinary General Meeting' (EGM). The document contains definitions, a letter from the board, and appendices explaining the terms of the scheme. This type of document, which provides information to shareholders to solicit their vote on specific proposals at an upcoming meeting, is classified as a Proxy Solicitation & Information Statement.
2026-03-02 English
CHANGE OF THE TRUSTEE OF H SHARE AWARD SCHEME
Board/Management Information Classification · 95% confidence The document is an official announcement from Vigonvita Life Sciences Co., Ltd. regarding a change in the trustee for their H Share Award Scheme. This relates to corporate governance and operational management of a share-based incentive plan. Since it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes), and it is a specific corporate announcement regarding board/management-approved operational changes, it falls under the general regulatory announcement category.
2026-03-02 English
ANNOUNCEMENT - BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING
AGM Information Classification · 98% confidence The document is an announcement regarding the book closure period for an upcoming Extraordinary General Meeting (EGM). It specifies the date, time, and location of the meeting, as well as the procedures for shareholders to attend and vote. It does not contain the actual proxy materials or the voting results themselves, but rather serves as a formal regulatory notice regarding the meeting logistics. Given the nature of the announcement as a regulatory disclosure regarding a shareholder meeting, it fits best under the 'Regulatory Filings' category as it does not meet the criteria for a full Proxy Solicitation (PSI) or a Voting Results announcement (DVA).
2026-03-02 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.